Exelixis Inc (EXEL) 5.98 $EXEL
How Much Could Exelixis Really Be Worth?
Sean Williams, The Motley Fool - Motley Fool - Fri Oct 09, 1:03PM CDT
Image source: Federal Reserve Bank of New York. Shareholders of biotechnology company Exelixis have had an exceptional year in spite of witnessing many biotech stocks giving back all of their gains for the year. Since Dec. 31, 2014, and through...
EXEL: 5.98 (+0.13)
Roche (RHHBY) Reports Positive Data on Skin Cancer Drugs
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 3:55PM CDT
Roche (RHHBY) announced positive data from a phase III study, coBRIM, on Zelboraf in combination with Cotellic (cobimetinib).
ABT: 41.89 (+0.73), NVO: 54.61 (-0.12), EXEL: 5.98 (+0.13)
Exelixis Announces Positive Overall Survival Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma
Business Wire - Tue Oct 06, 12:00AM CDT
Exelixis, Inc. (NASDAQ:EXEL) today announced positive overall survival (OS) results from coBRIM, the phase 3 pivotal trial evaluating cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma carrying a BRAF V600 mutation. Exelixis' collaborator Genentech, a member of the Roche Group, informed the company that coBRIM met its secondary endpoint of demonstrating a statistically significant and clinically meaningful increase in overall survival for patients receiving the combination of cobimetinib and vemurafenib, as compared to vemurafenib monotherapy. Ongoing study monitoring did not identify any new safety signals. Long-term safety data are expected later this year. These data will be the subject of a presentation at an upcoming medical meeting.
EXEL: 5.98 (+0.13)
Kidney Cancer Drug Boxing Match
Brian Orelli, The Motley Fool - Motley Fool - Sun Oct 04, 12:20PM CDT
Let the kidney cancer battle begin. In this corner, weighing in at a market cap around $100 billion, is Bristol-Myers Squibb and its immunotherapy drug Opdivo. And in this corner, weighing in at a mere $1.3 billion, is Exelixis and its...
BMY: 61.44 (+0.93), NVS: 91.90 (-0.71), EXEL: 5.98 (+0.13)
10 Best Nasdaq Biotech Stocks in the Third Quarter
at The Street - Wed Sep 30, 3:36PM CDT
Here are the 10 stocks in the biotech sector which had the best third-quarter.
CARA: 14.40 (-0.18), MYGN: 39.19 (-0.19), ZSPH: 66.89 (+1.72), MDCO: 34.88 (+0.07), LXRX: 11.59 (-0.05), INCY: 105.00 (+1.56), SCMP: 18.19 (-1.21), ANAC: 115.06 (+2.13), CNCE: 20.87 (+0.62), EXEL: 5.98 (+0.13)
Technical Review on Healthcare and Financial Sectors -- Two Harbors Investments, Hudson City Bancorp, Novavax, Opko Health and Exelixis
PR Newswire - Wed Sep 30, 9:31AM CDT
ACI Association has initiated research coverage on the following equities: Two Harbors Investments Corp (NYSE: TWO), Hudson City Bancorp, Inc. (NASDAQ: HCBK), Novavax, Inc. (NASDAQ: NVAX), Opko Health Inc (NYSE: OPK), Exelixis, Inc. (NASDAQ: EXEL). On Tuesday, September 29, 2015, Nasdaq ended at 4517.32, down 0.59%, Dow Jones advanced 0.30%, to finish the day at 16049.13, and the S&P closed at 1884.09, up 0.12%. Register for your complimentary reports at the links given below.
OPK: 8.90 (+0.26), NVAX: 8.04 (+0.43), TWO: 9.13 (+0.01), HCBK: 9.99 (-0.05), EXEL: 5.98 (+0.13)
4 Stocks Under $10 Making Big Moves Higher
at The Street - Tue Sep 29, 1:46PM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
PBMD: 1.22 (+0.05), MCUR: 3.84 (+0.16), IPI: 6.91 (+0.18), EXEL: 5.98 (+0.13)
Don't Panic! These 3 Beaten Down Biotech Stocks Are Now Great Buys
George Budwell, The Motley Fool - Motley Fool - Tue Sep 29, 12:03PM CDT
The moody market has taken its wrath out on biotech stocks far and wide in September. In fact, biotechs are some of the worst-performing stocks for the month: As the cover to "The Hitchhiker's Guide to the Galaxy" emphatically reminds us,...
AGEN: 4.81 (+0.03), TRVN: 10.13 (+0.26), EXEL: 5.98 (+0.13)
Exelixis Announces Positive Results from METEOR Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma Presented at European Cancer Congress 2015
Business Wire - Fri Sep 25, 5:09PM CDT
--- Cabozantinib showed a strong trend towards improving overall survival as compared to everolimus at an interim analysis -
EXEL: 5.98 (+0.13)
Bristol, Exelixis Drugs Demonstrate Treatment Benefit in Kidney Cancer
at The Street - Fri Sep 25, 5:02PM CDT
Bristol's Opdivo is likely to be used ahead of Exelixis' Cometriq to treat advanced kidney cancer patients, doctor says.
PFE: 33.24 (+0.15), MRK: 50.95 (-0.07), BMY: 61.44 (+0.93), EXEL: 5.98 (+0.13), NVS: 91.90 (-0.71)
European CHMP Adopts Positive Opinion for Cobimetinib in Combination with Vemurafenib for the Treatment of Advanced Melanoma
Business Wire - Fri Sep 25, 6:41AM CDT
Exelixis, Inc. (NASDAQ:EXEL) today announced that the European Medicines Agency's Committee for Medical Products for Human Use (CHMP) has adopted a positive opinion of the Marketing Authorization Application for cobimetinib, a selective MEK inhibitor discovered by Exelixis, in combination with vemurafenib for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma. The CHMP's positive opinion will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union. The European Commission is expected to release its final decision regarding the approval of the combination of cobimetinib and vemurafenib by the end of 2015.
EXEL: 5.98 (+0.13)
Covered Call Alerts For Exelixis, Heron Therapeutics, BP, Micron and Qihoo 360 Technology Released By InvestorsObserver
PR Newswire - Thu Sep 24, 8:31AM CDT
InvestorsObserver has issued critical PriceWatch Alerts for EXEL, HRTX, BP, QIHU and ARIA.
QIHU: 52.00 (-1.42), HRTX: 25.72 (-0.93), BP: 35.96 (unch), ARIA: 7.02 (+0.21), EXEL: 5.98 (+0.13)
Technical Coverage on Stocks from Diverse Sectors - CME Group, Commerce Bancshares, Conatus Pharmaceuticals, Exelixis and CTI BioPharma
PR Newswire - Thu Sep 24, 8:09AM CDT
ACI Association has initiated research coverage on the following equities: CME Group Inc. (NASDAQ: CME), Commerce Bancshares, Inc. (NASDAQ: CBSH), Conatus Pharmaceuticals Inc. (NASDAQ: CNAT), Exelixis, Inc. (NASDAQ: EXEL), CTI BioPharma Corp. (NASDAQ: CTIC). On Wednesday, September 23, 2015, NASDAQ ended at 4,752.74, down 0.08%, Dow Jones declined 0.31% to finish the day at 16,279.89, and the S&P closed at 1,938.76, down 0.20%. Register for your complimentary reports at the links given below.
CME: 88.30 (-1.58), CNAT: 4.21 (-0.06), CTIC: 1.63 (-0.01), CBSH: 46.31 (-0.38), EXEL: 5.98 (+0.13)
Exelixis Announces Key Senior Leadership Hires in Medical Affairs, Sales, and Marketing to Support Commercialization of Cabozantinib and Cobimetinib
Business Wire - Thu Sep 24, 7:00AM CDT
Exelixis, Inc. (NASDAQ:EXEL) today announced three high-level appointments as the company prepares for the potential commercialization of its lead compound, cabozantinib, for the treatment of advanced renal cell carcinoma (RCC) following positive results from the METEOR pivotal phase 3 trial. William Berg, M.D. has joined the company as Senior Vice President of Medical Affairs, Jonathan Berndt as Vice President of Sales, and Gregg Bernier as Vice President of Marketing.
EXEL: 5.98 (+0.13)
Exelixis to Host Investor/Analyst Webcast During European Cancer Congress 2015
Business Wire - Tue Sep 22, 4:08PM CDT
--- Cabozantinib and Exelixis-Discovered Cobimetinib to be Subject of Three Presentations -
EXEL: 5.98 (+0.13)
Follicular Thyroid Cancer Pipeline Review, H2 2015 - 5 Companies & 8 Drug Profiles
M2 - Tue Sep 22, 11:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d2l7z4/follicular) has announced the addition of the "Follicular Thyroid Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Follicular Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Follicular Thyroid Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca Plc - Eisai Co., Ltd. - Exelixis, Inc. - Novartis AG - Pfizer Inc. Drug Profiles - cabozantinib s-malate - dabrafenib mesylate - everolimus - lenvatinib - pasireotide - sunitinib malate - tetraiodothyroacetic acid - vandetanib For more information visit http://www.researchandmarkets.com/research/d2l7z4/follicular
PFE: 33.24 (+0.15), AZN: 32.23 (-0.16), NVS: 91.90 (-0.71), EXEL: 5.98 (+0.13)
Biotechnology Stocks Technical Study -- Exelixis, XOMA Corp., Enzon Pharma, Peregrine Pharma, and StemCells
PR Newswire - Mon Sep 21, 7:50AM CDT
Equity Research Institute has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), XOMA Corporation (NASDAQ: XOMA), Enzon Pharmaceuticals Inc. (NASDAQ: ENZN), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), and StemCells Inc. (NASDAQ: STEM). Free research report on Exelixis can be accessed at https://www.erionline.net/EXEL.pdf On Friday, September 18, 2015, the NASDAQ Composite ended at 4,827.23, down 1.36%, the Dow Jones Industrial Average declined 1.74%, to finish the day at 16,384.79, and the S&P 500 closed at 1,958.03, down 1.62%. The losses were broad based as eight out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
ENZN: 0.86 (-0.07), STEM: 0.44 (+0.04), PPHM: 1.07 (unch), XOMA: 0.99 (+0.04), EXEL: 5.98 (+0.13)
'Sell the News' Reaction Is Quite Logical
at The Street - Fri Sep 18, 3:08PM CDT
After poor close on Thursday, market trends down all day.
TRVN: 10.13 (+0.26), SPY: 201.33 (+0.12), LBIO: 6.48 (+0.03), ONTY: 2.88 (+0.08), EXEL: 5.98 (+0.13)
Time to Do Some Stock-Picking
at The Street - Fri Sep 18, 10:12AM CDT
But manage trades closely as opportunities develop.
TRVN: 10.13 (+0.26), SPY: 201.33 (+0.12), LBIO: 6.48 (+0.03), ONTY: 2.88 (+0.08), EXEL: 5.98 (+0.13)
Biotech Stock Mailbag: Bristol, Exelixis, Lion Bio, GW Pharma
at The Street - Fri Sep 18, 5:11AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
GWPH: 87.75 (+0.45), ICPT: 181.90 (-8.81), LBIO: 6.48 (+0.03), RMTI: 8.99 (+0.78), BMY: 61.44 (+0.93), KERX: 4.25 (+0.23), NVS: 91.90 (-0.71), EXEL: 5.98 (+0.13)
How Much Could Exelixis Really Be Worth?
Sean Williams, The Motley Fool - Motley Fool - Fri Oct 09, 1:03PM CDT
Image source: Federal Reserve Bank of New York. Shareholders of biotechnology company Exelixis have had an exceptional year in spite of witnessing many biotech stocks giving back all of their gains for the year. Since Dec. 31, 2014, and through...
EXEL: 5.98 (+0.13)
Roche (RHHBY) Reports Positive Data on Skin Cancer Drugs
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 3:55PM CDT
Roche (RHHBY) announced positive data from a phase III study, coBRIM, on Zelboraf in combination with Cotellic (cobimetinib).
ABT: 41.89 (+0.73), NVO: 54.61 (-0.12), EXEL: 5.98 (+0.13)
Exelixis Announces Positive Overall Survival Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma
Business Wire - Tue Oct 06, 12:00AM CDT
Exelixis, Inc. (NASDAQ:EXEL) today announced positive overall survival (OS) results from coBRIM, the phase 3 pivotal trial evaluating cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma carrying a BRAF V600 mutation. Exelixis' collaborator Genentech, a member of the Roche Group, informed the company that coBRIM met its secondary endpoint of demonstrating a statistically significant and clinically meaningful increase in overall survival for patients receiving the combination of cobimetinib and vemurafenib, as compared to vemurafenib monotherapy. Ongoing study monitoring did not identify any new safety signals. Long-term safety data are expected later this year. These data will be the subject of a presentation at an upcoming medical meeting.
EXEL: 5.98 (+0.13)
Kidney Cancer Drug Boxing Match
Brian Orelli, The Motley Fool - Motley Fool - Sun Oct 04, 12:20PM CDT
Let the kidney cancer battle begin. In this corner, weighing in at a market cap around $100 billion, is Bristol-Myers Squibb and its immunotherapy drug Opdivo. And in this corner, weighing in at a mere $1.3 billion, is Exelixis and its...
BMY: 61.44 (+0.93), NVS: 91.90 (-0.71), EXEL: 5.98 (+0.13)
10 Best Nasdaq Biotech Stocks in the Third Quarter
at The Street - Wed Sep 30, 3:36PM CDT
Here are the 10 stocks in the biotech sector which had the best third-quarter.
CARA: 14.40 (-0.18), MYGN: 39.19 (-0.19), ZSPH: 66.89 (+1.72), MDCO: 34.88 (+0.07), LXRX: 11.59 (-0.05), INCY: 105.00 (+1.56), SCMP: 18.19 (-1.21), ANAC: 115.06 (+2.13), CNCE: 20.87 (+0.62), EXEL: 5.98 (+0.13)
Technical Review on Healthcare and Financial Sectors -- Two Harbors Investments, Hudson City Bancorp, Novavax, Opko Health and Exelixis
PR Newswire - Wed Sep 30, 9:31AM CDT
ACI Association has initiated research coverage on the following equities: Two Harbors Investments Corp (NYSE: TWO), Hudson City Bancorp, Inc. (NASDAQ: HCBK), Novavax, Inc. (NASDAQ: NVAX), Opko Health Inc (NYSE: OPK), Exelixis, Inc. (NASDAQ: EXEL). On Tuesday, September 29, 2015, Nasdaq ended at 4517.32, down 0.59%, Dow Jones advanced 0.30%, to finish the day at 16049.13, and the S&P closed at 1884.09, up 0.12%. Register for your complimentary reports at the links given below.
OPK: 8.90 (+0.26), NVAX: 8.04 (+0.43), TWO: 9.13 (+0.01), HCBK: 9.99 (-0.05), EXEL: 5.98 (+0.13)
4 Stocks Under $10 Making Big Moves Higher
at The Street - Tue Sep 29, 1:46PM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
PBMD: 1.22 (+0.05), MCUR: 3.84 (+0.16), IPI: 6.91 (+0.18), EXEL: 5.98 (+0.13)
Don't Panic! These 3 Beaten Down Biotech Stocks Are Now Great Buys
George Budwell, The Motley Fool - Motley Fool - Tue Sep 29, 12:03PM CDT
The moody market has taken its wrath out on biotech stocks far and wide in September. In fact, biotechs are some of the worst-performing stocks for the month: As the cover to "The Hitchhiker's Guide to the Galaxy" emphatically reminds us,...
AGEN: 4.81 (+0.03), TRVN: 10.13 (+0.26), EXEL: 5.98 (+0.13)
Exelixis Announces Positive Results from METEOR Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma Presented at European Cancer Congress 2015
Business Wire - Fri Sep 25, 5:09PM CDT
--- Cabozantinib showed a strong trend towards improving overall survival as compared to everolimus at an interim analysis -
EXEL: 5.98 (+0.13)
Bristol, Exelixis Drugs Demonstrate Treatment Benefit in Kidney Cancer
at The Street - Fri Sep 25, 5:02PM CDT
Bristol's Opdivo is likely to be used ahead of Exelixis' Cometriq to treat advanced kidney cancer patients, doctor says.
PFE: 33.24 (+0.15), MRK: 50.95 (-0.07), BMY: 61.44 (+0.93), EXEL: 5.98 (+0.13), NVS: 91.90 (-0.71)
European CHMP Adopts Positive Opinion for Cobimetinib in Combination with Vemurafenib for the Treatment of Advanced Melanoma
Business Wire - Fri Sep 25, 6:41AM CDT
Exelixis, Inc. (NASDAQ:EXEL) today announced that the European Medicines Agency's Committee for Medical Products for Human Use (CHMP) has adopted a positive opinion of the Marketing Authorization Application for cobimetinib, a selective MEK inhibitor discovered by Exelixis, in combination with vemurafenib for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma. The CHMP's positive opinion will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union. The European Commission is expected to release its final decision regarding the approval of the combination of cobimetinib and vemurafenib by the end of 2015.
EXEL: 5.98 (+0.13)
Covered Call Alerts For Exelixis, Heron Therapeutics, BP, Micron and Qihoo 360 Technology Released By InvestorsObserver
PR Newswire - Thu Sep 24, 8:31AM CDT
InvestorsObserver has issued critical PriceWatch Alerts for EXEL, HRTX, BP, QIHU and ARIA.
QIHU: 52.00 (-1.42), HRTX: 25.72 (-0.93), BP: 35.96 (unch), ARIA: 7.02 (+0.21), EXEL: 5.98 (+0.13)
Technical Coverage on Stocks from Diverse Sectors - CME Group, Commerce Bancshares, Conatus Pharmaceuticals, Exelixis and CTI BioPharma
PR Newswire - Thu Sep 24, 8:09AM CDT
ACI Association has initiated research coverage on the following equities: CME Group Inc. (NASDAQ: CME), Commerce Bancshares, Inc. (NASDAQ: CBSH), Conatus Pharmaceuticals Inc. (NASDAQ: CNAT), Exelixis, Inc. (NASDAQ: EXEL), CTI BioPharma Corp. (NASDAQ: CTIC). On Wednesday, September 23, 2015, NASDAQ ended at 4,752.74, down 0.08%, Dow Jones declined 0.31% to finish the day at 16,279.89, and the S&P closed at 1,938.76, down 0.20%. Register for your complimentary reports at the links given below.
CME: 88.30 (-1.58), CNAT: 4.21 (-0.06), CTIC: 1.63 (-0.01), CBSH: 46.31 (-0.38), EXEL: 5.98 (+0.13)
Exelixis Announces Key Senior Leadership Hires in Medical Affairs, Sales, and Marketing to Support Commercialization of Cabozantinib and Cobimetinib
Business Wire - Thu Sep 24, 7:00AM CDT
Exelixis, Inc. (NASDAQ:EXEL) today announced three high-level appointments as the company prepares for the potential commercialization of its lead compound, cabozantinib, for the treatment of advanced renal cell carcinoma (RCC) following positive results from the METEOR pivotal phase 3 trial. William Berg, M.D. has joined the company as Senior Vice President of Medical Affairs, Jonathan Berndt as Vice President of Sales, and Gregg Bernier as Vice President of Marketing.
EXEL: 5.98 (+0.13)
Exelixis to Host Investor/Analyst Webcast During European Cancer Congress 2015
Business Wire - Tue Sep 22, 4:08PM CDT
--- Cabozantinib and Exelixis-Discovered Cobimetinib to be Subject of Three Presentations -
EXEL: 5.98 (+0.13)
Follicular Thyroid Cancer Pipeline Review, H2 2015 - 5 Companies & 8 Drug Profiles
M2 - Tue Sep 22, 11:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d2l7z4/follicular) has announced the addition of the "Follicular Thyroid Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Follicular Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Follicular Thyroid Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca Plc - Eisai Co., Ltd. - Exelixis, Inc. - Novartis AG - Pfizer Inc. Drug Profiles - cabozantinib s-malate - dabrafenib mesylate - everolimus - lenvatinib - pasireotide - sunitinib malate - tetraiodothyroacetic acid - vandetanib For more information visit http://www.researchandmarkets.com/research/d2l7z4/follicular
PFE: 33.24 (+0.15), AZN: 32.23 (-0.16), NVS: 91.90 (-0.71), EXEL: 5.98 (+0.13)
Biotechnology Stocks Technical Study -- Exelixis, XOMA Corp., Enzon Pharma, Peregrine Pharma, and StemCells
PR Newswire - Mon Sep 21, 7:50AM CDT
Equity Research Institute has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), XOMA Corporation (NASDAQ: XOMA), Enzon Pharmaceuticals Inc. (NASDAQ: ENZN), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), and StemCells Inc. (NASDAQ: STEM). Free research report on Exelixis can be accessed at https://www.erionline.net/EXEL.pdf On Friday, September 18, 2015, the NASDAQ Composite ended at 4,827.23, down 1.36%, the Dow Jones Industrial Average declined 1.74%, to finish the day at 16,384.79, and the S&P 500 closed at 1,958.03, down 1.62%. The losses were broad based as eight out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
ENZN: 0.86 (-0.07), STEM: 0.44 (+0.04), PPHM: 1.07 (unch), XOMA: 0.99 (+0.04), EXEL: 5.98 (+0.13)
'Sell the News' Reaction Is Quite Logical
at The Street - Fri Sep 18, 3:08PM CDT
After poor close on Thursday, market trends down all day.
TRVN: 10.13 (+0.26), SPY: 201.33 (+0.12), LBIO: 6.48 (+0.03), ONTY: 2.88 (+0.08), EXEL: 5.98 (+0.13)
Time to Do Some Stock-Picking
at The Street - Fri Sep 18, 10:12AM CDT
But manage trades closely as opportunities develop.
TRVN: 10.13 (+0.26), SPY: 201.33 (+0.12), LBIO: 6.48 (+0.03), ONTY: 2.88 (+0.08), EXEL: 5.98 (+0.13)
Biotech Stock Mailbag: Bristol, Exelixis, Lion Bio, GW Pharma
at The Street - Fri Sep 18, 5:11AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
GWPH: 87.75 (+0.45), ICPT: 181.90 (-8.81), LBIO: 6.48 (+0.03), RMTI: 8.99 (+0.78), BMY: 61.44 (+0.93), KERX: 4.25 (+0.23), NVS: 91.90 (-0.71), EXEL: 5.98 (+0.13)
